XNYS · Healthcare · Drug Manufacturers - General
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 1.61 | 2.04 | +26.71% | $12.97B | ✅ Beat | +0.43% | -1.09% | +2.65% |
| 2026-04-30 | Q1 2026 | 1.43 | 1.58 | +10.49% | $11.49B | ✅ Beat | -0.85% | -7.16% | -5.63% |
| 2026-02-05 |
| Q4 2025 |
| 1.19 |
| 1.26 |
| +5.88% |
| $12.50B |
| ✅ Beat |
| -0.21% |
| +0.57% |
| +1.29% |
| 2025-10-30 | Q3 2025 | 1.51 | 1.63 | +7.95% | $12.22B | ✅ Beat | — | — | — |
| 2025-07-31 | Q2 2025 | 1.15 | 1.46 | +26.96% | $12.30B | ✅ Beat | — | — | — |
| 2025-04-24 | Q1 2025 | 1.49 | 1.80 | +20.81% | $11.20B | ✅ Beat | — | — | — |
| 2025-02-06 | Q4 2024 | 1.47 | 1.67 | +13.61% | $12.34B | ✅ Beat | — | — | — |
| 2024-10-31 | Q3 2024 | 1.49 | 1.80 | +20.81% | $11.89B | ✅ Beat | — | — | — |
Showing last 8 quarters.